BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab (BV) plus paclitaxel/carboplatin (PC) as first-line treatment (tx) for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC).

L. Faoro; J. D. Hainsworth; D. A. Karlin; J. E. Huang; L. Fang; F. A. Scappaticci

doi:10.1200/jco.2010.28.15_suppl.7583

BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab (BV) plus paclitaxel/carboplatin (PC) as first-line treatment (tx) for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7583 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7583-7583

Author(s):

L. Faoro ◽

J. D. Hainsworth ◽

D. A. Karlin ◽

J. E. Huang ◽

L. Fang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e3181f94ad4 ◽

2011 ◽

Vol 6 (1) ◽

pp. 109-114 ◽

Cited By ~ 41

Author(s):

John D. Hainsworth ◽

Liang Fang ◽

Jane E. Huang ◽

David Karlin ◽

Kenneth Russell ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7

Lung Cancer ◽

10.1016/s0169-5002(16)30086-1 ◽

2016 ◽

Vol 91 ◽

pp. S25

Author(s):

K.J. O'Byrne ◽

K. Park ◽

E. Tan ◽

L. Zhang ◽

V. Hirsh ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

LBA2_PR Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)

Annals of Oncology ◽

10.1093/annonc/mdv586.02 ◽

2015 ◽

Vol 26 ◽

pp. ix161 ◽

Cited By ~ 10

Author(s):

K. Park ◽

E.-H. Tan ◽

L. Zhang ◽

V. Hirsh ◽

K. O'Byrne ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8056 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8056-8056

Author(s):

Masayuki Takeda ◽

Takashi Seto ◽

Hidetoshi Hayashi ◽

Morihito Okada ◽

Koichi Azuma ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727089161.793539631 ◽

2017 ◽

Author(s):

Patrick Nana-Sinkam

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase 1 ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

The Lancet Oncology ◽

10.1016/s1470-2045(16)30624-6 ◽

2017 ◽

Vol 18 (1) ◽

pp. 31-41 ◽

Cited By ~ 430

Author(s):

Matthew D Hellmann ◽

Naiyer A Rizvi ◽

Jonathan W Goldman ◽

Scott N Gettinger ◽

Hossein Borghaei ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase 1 ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30167-6 ◽

2019 ◽

Vol 20 (7) ◽

pp. 924-937 ◽

Cited By ~ 202

Author(s):

Howard West ◽

Michael McCleod ◽

Maen Hussein ◽

Alessandro Morabito ◽

Achim Rittmeyer ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

P48.09 Anlotinib Plus Etoposide and Carboplatin as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: A Single Arm Phase II Trial

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.01.879 ◽

2021 ◽

Vol 16 (3) ◽

pp. S503

Author(s):

B. Han ◽

W. Zhang ◽

B. Zhang ◽

Y. Chen ◽

Y. Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Extensive Stage ◽

First Line Treatment

Download Full-text

9095 POSTER Prospective Phase II Trial of a Combination of Gemcitabine and UFT as First-line Treatment in Elderly Patients With Advanced Non-small Cell Lung Cancer

European Journal of Cancer ◽

10.1016/s0959-8049(11)72407-8 ◽

2011 ◽

Vol 47 ◽

pp. S621

Author(s):

J. Baek ◽

J. Ahn ◽

Y. Jegal ◽

C. Park ◽

Y. Lee ◽

...

Keyword(s):

Lung Cancer ◽

Elderly Patients ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Prospective Phase ◽

First Line Treatment

Download Full-text

Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients

Anticancer Research ◽

10.21873/anticanres.12661 ◽

2018 ◽

Vol 38 (6) ◽

pp. 3779-3784 ◽

Cited By ~ 1

Author(s):

HIROAKI TAKEOKA ◽

KAZUHIKO YAMADA ◽

YOSHIKO NAITO ◽

NORIKAZU MATSUO ◽

HIDENOBU ISHII ◽

...

Keyword(s):

Lung Cancer ◽

Elderly Patients ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

First Line Treatment

Download Full-text